Established, emerging and future roles of PET/CT in the management of colorectal cancer.
Positron-emission tomography-computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC).
Herbertson
R A
RA
Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia. rebecca.herbertson@ludwig.edu.au
Scarsbrook
A F
AF
Lee
S T
ST
Tebbutt
N
N
Scott
A M
AM
D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D049268:Positron-Emission Tomography / Q000191:economics / Q000379:methods* / Q000639:trends; D019275:Radiopharmaceuticals; D011880:Radiotherapy Planning, Computer-Assisted; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000191:economics / Q000379:methods* / Q000639:trends; D006113:United Kingdom
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18